1331 - Comparison of survival in patients with advanced lung adenocarcinoma treated before and after gefitinib approval in china

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Presenter yuankai Shi
Authors Y. Shi1, Y. Liu2, X. Hao1, J. Li1, X. Hu1, Y. Wang1, Z. Wang3, H. Wang3, X. Han4, X. Zhang3
  • 1Oncology, Cancer Hospital-China Academy of Medical Sciences, 100021 - Beijing/CN
  • 2Oncology Dept., Cancer Hospital-China Academy of Medical Sciences, 100021 - Beijing/CN
  • 3Medical Oncology, Cancer Hospital-Chao Yang District BeijingCAMS and PUMC, CN-100021 - Beijing/CN
  • 4Clinical Labortary, Cancer Hospital-China Academy of Medical Sciences, 100021 - Beijing/CN

Abstract

Objective

This study compared the overall survival (OS) between advanced lung adenocarcinoma patients of before and after gefitinib approval in China.

Methods

The clinical data of 558 advanced lung adenocarcinoma patients who ever received palliative chemotherapy were reviewed retrospectively. According to a matched-pair case-control study design, 255 patients of before gefitinib approval who only received palliative chemotherapy and 255 patients of after gefitinib approval who received gefitinib treatment were matched by age, sex and smoking history.

Results

The median survival time (MST) of 510 advanced lung adenocarcinoma patients from the date of first-line palliative therapy was 22.8 months. MST was significantly longer among the patients treated with gefitinib after gefitinib approval compared with the patients treated before gefitinib approval (33.5 vs. 14.1months, p < 0.001). Multivariate analysis showed that the independent prognostic factors to significantly improve OS of 510 patients included gefitinib treatment (hazard ratio 0.175, P<0.001), age < 60 years, non-smoker, no hepatic metastasis and receiving ≥ 3 prior cytotoxic chemotherapy regimens. Patients after gefitinib approval showed significantly longer OS in almost all clinical factors subgroups (p < 0.001) including age, sex, smoking history, ECOG PS 0-1, tumor stage, sites of metastasis including lung, Pleural, bone, brain, adrenal gland and liver and numbers of prior cytotoxic chemotherapy regimens, except ECOG PS ≥2 subgroup(p = 0.090). Multivariate analysis showed that non-smoker, receiving ≥3 prior cytotoxic chemotherapy regimens and EGFR mutation were associated with longer OS of 255 patients after gefitinib approval.

Conclusion

Gefitinib treatment significantly improved the survival of the patients with advanced lung adenocarcinoma in China.

Disclosure

All authors have declared no conflicts of interest.